MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-19-2025
OpGen Total Assets 2011-2026 | OPGN
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets OpGen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.86 M | 1.88 M | 25.8 M | 71.7 M | 49.8 M | 10.4 M | 8.95 M | 6.62 M | 8.98 M | 13.8 M | 2.65 M | 3.16 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 71.7 M | 1.88 M | 17.8 M |
Quarterly Total Assets OpGen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.6 M | 13.2 M | 9.42 M | 9.86 M | 5.47 M | 2.87 M | - | 1.88 M | 18.1 M | 22.4 M | 26.5 M | 25.8 M | 33 M | 48.8 M | 64.3 M | 71.7 M | 62.3 M | 68.6 M | 75.2 M | 49.8 M | 49.8 M | 49.8 M | 49.8 M | 10.4 M | 10.4 M | 10.4 M | 10.4 M | 8.95 M | 8.95 M | 8.95 M | 8.95 M | 6.62 M | 6.62 M | 6.62 M | 6.62 M | 8.98 M | 8.98 M | 8.98 M | 8.98 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 2.65 M | 2.65 M | 2.65 M | 2.65 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 75.2 M | 1.88 M | 21.2 M |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
94.3 M | $ 13.65 | -0.44 % | $ 99.4 M |  Israel |
 |
Aspira Women's Health
AWH
|
17.4 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Bioventus
BVS
|
684 M | $ 8.87 | 2.9 % | $ 591 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
 |
Charles River Laboratories International
CRL
|
7.14 B | $ 151.97 | -2.34 % | $ 7.53 B | USA |
 |
Castle Biosciences
CSTL
|
531 M | $ 25.83 | 1.06 % | $ 717 M | USA |
 |
CareDx, Inc
CDNA
|
413 M | $ 17.32 | 1.82 % | $ 923 M | USA |
 |
DexCom
DXCM
|
6.34 B | $ 66.34 | 3.27 % | $ 25.9 B | USA |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
5.86 B | $ 103.85 | 0.27 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 14.95 | 1.22 % | $ 452 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
97.2 M | $ 17.29 | -3.3 % | $ 2.24 B | USA |
 |
Guardant Health
GH
|
2.01 B | $ 87.18 | 1.98 % | $ 10.9 B | USA |
 |
Anixa Biosciences
ANIX
|
16.1 M | $ 2.84 | 0.35 % | $ 92.2 K | USA |
 |
Danaher Corporation
DHR
|
83.5 B | $ 191.39 | 2.17 % | $ 136 B | USA |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
16.9 B | $ 97.61 | -0.73 % | $ 8.05 B |  Irlanda |
 |
IQVIA Holdings
IQV
|
29.9 B | $ 164.89 | 0.1 % | $ 28.3 B | USA |
 |
Illumina
ILMN
|
6.3 B | $ 119.28 | 0.29 % | $ 19 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 198.94 | -0.38 % | $ 22.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
5.69 B | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
10.7 B | $ 111.83 | 0.28 % | $ 34 B | USA |
 |
BioNano Genomics
BNGO
|
76.7 M | $ 1.11 | - | $ 1.41 M | USA |
 |
DarioHealth Corp.
DRIO
|
96.4 M | $ 8.42 | -6.44 % | $ 239 M | Israel |
 |
Lantheus Holdings
LNTH
|
2.23 B | $ 78.5 | -1.25 % | $ 5.3 B | USA |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
95.3 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
1.98 B | $ 453.64 | 0.72 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
3.71 B | $ 1 198.71 | 2.13 % | $ 24.7 B |  Schweiz |
 |
Celcuity
CELC
|
245 M | $ 114.9 | 0.6 % | $ 4.53 B | USA |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
Neogen Corporation
NEOG
|
3.44 B | $ 9.11 | 0.22 % | $ 1.98 B | USA |
 |
National Research Corporation
NRC
|
135 M | $ 17.4 | 5.33 % | $ 389 M | USA |
 |
NeoGenomics
NEO
|
1.36 B | $ 8.24 | 4.57 % | $ 1.06 B | USA |
 |
Invitae Corporation
NVTA
|
1.95 B | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
1.39 B | $ 197.68 | 5.23 % | $ 19.5 B | USA |
 |
OPKO Health
OPK
|
2.2 B | $ 1.19 | - | $ 826 M | USA |
 |
Pacific Biosciences of California
PACB
|
784 M | $ 1.36 | 2.26 % | $ 408 M | USA |